Ann: Ethics Application Submitted for Phase 1 Trial, page-9

Hi Lachie, IF we meet Phase 1 endpoints of safety, I believe our company, Argenica, should be valued at between $150-200 million Australian.

That valuation ISN'T just for meeting Phase 1 endpoints, although is also based off current and former peer valuations, it's based off the total addressable market sizes for our different indications (and how that might excite future partnerships with big pharma) it is based off the people and partners we have, it is based off the more than 10 years of work and pre-clinical data that the drug has generated.

Everyone is of course entitled to their own opinions and valuations, the above is mine only and should not be seen as a recommendation or advice.